UnknownNot Applicable

NGS Combined With RNAseq on Tumor Immune Escape in NSCLC

China100 participantsStarted 2018-12-01

Plain-language summary

Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Non-small cell lung cancer patient First-line chemotherapy with platinum-based chemotherapy Exclusion Criteria: EGFR mutant positive Alk mutant positive

What they're measuring

numbers of immune cells

Timeframe: 24 months

Trial details

NCT IDNCT03764917

SponsorShanghai Pulmonary Hospital, Shanghai, China

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-12-31

View on ClinicalTrials.gov More Non-small Cell Lung Cancer trials